Hair Follicle Keratinocytes

I have rarely discussed hair follicle keratinocytes on this blog. However, a new study published by EpiBiotech CEO Jong-Hyuk Sung in collaboration with researchers from Seoul National University College of Pharmacy has given me the opportunity.

Hair Follicle Keratinocytes
Hair Follicle Keratinocytes. Source: Archives of Dermatological Research, December 2024.

Keratinocytes of the Hair Follicles and Skin

The new December 2024 study (that is not yet available in full) is titled:

Differential expression of androgen receptor and 5-α reductase isoforms in skin cells“.

A summary of its findings can be read here (h/t “Ben”). Interestingly, an older 2014 study that I came across while writing this post is titled: “Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications.”

The researchers used single-cell RNA sequencing technology to identify the expression sites of androgen receptors and 5-α reductase in human and mouse skin cells. They analyzed all three isozymes of 5α-reductase (encoded by the genes SRD5A1, SRD5A2, and SRD5A3). Past research has found that SRD5A2 is not expressed in the skin and hair follicles.

The study confirms that dihydrotestosterone (DHT) biosynthesis (the cause of pattern hair loss) is produced in the keratinocytes of skin and hair follicles. And not in dermal papilla cells (or dermal sheath cup cells) which are the main focus of hair multiplication research.

EpiBiotech CEO Seong-Hyeok Sung said:

“This study suggests a new mechanism for androgenetic alopecia treatment and opens up the possibility of a new approach targeting hair follicle keratinocytes, moving away from the existing dermal papilla cell-centered treatment method.”

Considering the diverse range of hair loss treatments and research that Epibiotech is focusing on (in a rapid manner), I am reluctant to put too much stock into their findings as yet.

Past Discussions of Keratinocytes on this Blog

When I started writing this post, I did a search of the past mentions of keratinocytes on this blog. Lo and behold, I found something unusual right off the bat.

“For decades, researchers studying aging and hair loss have focused on keratinocytes, the cells that make up the bulk of the hair follicle and eventually give rise to the hair fibre. But a study from the University of Calgary Faculty of Veterinary Medicine (UCVM) has found that it’s actually a small population of specialized cells within the hair follicle called fibroblasts, and the dermal stem cells that maintain them, that may cause hair loss.”

This says the opposite of what Jong-Hyuk Sung said in regards to the lack of importance given to keratinocytes in the past. My personal feeling is that Mr. Sung is correct and the importance given to keratinocytes has been less than that given to dermal stem cells. However, Dr. Bernaskie is a highly respected researcher, and perhaps the above pasted statement is not a direct quote from him.

  • In my 2017 interview with Stemson Therapeutics co-founder Dr. Alexey Terskikh, he said the following:

“Then DP cells will be mixed with keratinocytes within a specialized matrix scaffold and transplanted back into the same patient’s skin.”

  • When discussing fibroblast growth factors in past posts, I have noted that FGF7 (also called keratinocyte growth factor, or KGF) is required for hair growth. The much discussed and maligned Histogen (no longer active) was developing a Hair Stimulating Complex that included KGF as a key ingredient.

Stemson Therapeutics Shuts Down

Stemson TherapeuticsIn the worst news in the hair loss world in a few years, I have been notified that Stemson Therapeutics (US) has been forced to shut down due to funding issues. Over the past decade, this company represented the biggest hope for a real hair loss cure along with RIKEN (Japan) based Dr. Takashi Tsuji (OrganTech).

Stemson Therapeutics Ceases Operations

Below is the e-mail I just got from CEO Geoff Hamilton. It was in response to my e-mail to him yesterday regarding recent issues with layoffs at the company and their website stemsontx DOT com not working.

“Thanks for reaching out. Unfortunately, all is not OK. Due to lack of funding is this historically bad biotech funding market since 2022, Stemson has been forced to cease operations and shut down. I wish it were a different outcome. We were going after the holy grail and the most difficult approach to regenerate hair follicles, but one that could actually be curative.

It requires an enormous amount of investment, and the investment community didn’t have enough enthusiasm for it. Hopefully, someone will pick up where we left off in the future. I wish you all the best and happy holidays.”

And as a side note, Aderans and its hair multiplication procedure are truly cursed. The Japanese company’s hair multiplication subsidiary originally folded in 2013 despite significant promise. Their technology then got reincarnated in March 2024 after a new licensing deal with Stemson Therapeutics. Now they indirectly fold again.

For the time being, we have to look forward to the numerous new products that could be released in the near future that maintain one’s hair and regrow some recently lost hair. Hopefully, Shiseido’s newly released hair multiplication technology will be more effective than finasteride or minoxidil. For now, it is only available in Japan, a country that I inadvertently mentioned three times in this post.

Reversing long-standing baldness remains a pipe dream in the short term.